There is some really exciting news for patients with advanced prostate cancer — as an anti-androgen or anti-testosterone drug called darolutamide (brand name: Nubeqa) is showing promise in ...

For patients with metastatic hormone-sensitive prostate cancer (mHSPC), efficacy outcomes were improved following treatment with Nubeqa (darolutamide) in combination with androgen deprivation therapy ...

The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide) follows the publication of the results of the phase 3 ARASENS trial in the New England ...

New subgroup analysis from the investigational Phase III ARANOTE trial show that NUBEQA ® (darolutamide) plus androgen deprivation therapy (ADT) improved radiological progression-free survival ...

Nubeqa is one of Bayer's top drugs and a potential label expansion should further boost sales. The drug generated sales of more than €1 billion in the first nine months of 2024.

In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering ...

Triple therapy with darolutamide vs abiraterone for metastatic hormone-sensitive prostate cancer is associated with better clinical outcomes. Triplet therapy that includes darolutamide vs ...

Darolutamide plus ADT vs placebo plus ADT improves oncologic outcomes in patients with mHSPC regardless of disease volume, although the benefit is more pronounced among patients with low-volume ...

Data will include a subgroup analysis from the investigational Phase III ARANOTE trial, evaluating the efficacy and safety of NUBEQA ® (darolutamide) and androgen-deprivation therapy (ADT ...